Depression and dementia in Parkinson's disease. Catecholamine changes in the locus ceruleus, a basis for therapy.
Chan-Palay
V
V
F. Hoffman-La Roche Ltd., International Clinical Research CNS, Basel, Switzerland.
D000368:Aged; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002395:Catecholamines / Q000378:metabolism*; D003704:Dementia / Q000188:drug therapy / Q000473:pathology* / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy / Q000473:pathology* / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008125:Locus Coeruleus / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009474:Neurons / Q000473:pathology; D009483:Neuropsychological Tests; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy / Q000473:pathology* / Q000523:psychology; D014446:Tyrosine 3-Monooxygenase / Q000502:physiology
D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D002395:Catecholamines; D008996:Monoamine Oxidase Inhibitors; D014446:Tyrosine 3-Monooxygenase; D009638:Norepinephrine